It has been established that TPPC exerts potent anti-MRSA activity. Interestingly, when combined with beta-lactams, the antimicrobial activity of TPPC against MRSA is synergistically enhanced. In this ...

The world is facing the threat of 'superbugs' as these bacteria dubbed as methicillin-resistant Staphylococcus aureus (MRSA) have evolved into one of the most difficult-to-treat pathogens. A new study ...

Researchers have simplified the operation of an important class of chemical transformation: synthesis of beta-lactams, the intricate scaffold of many antibiotics. Their experimental protocol minimizes ...

Roche licenses investigational beta-lactamase inhibitor OP0595 OP0595 targets beta-lactamase enzymes in combination with new or existing beta-lactam antibiotics to enhance their effectiveness in ...

From superbug to… bug. Newly discovered chemical compounds can make MRSA bacteria vulnerable to the antibiotics they normally resist, restoring the old drug’s former powers. These drugs work by ...

What are some differences in the way different antibiotics work? originally appeared on Quora - the knowledge sharing network where compelling questions are answered by people with unique insights.

Full-dose challenges for emergency department (ED) patients with moderate, severe, and unknown beta-lactam allergies can safely reduce unnecessary antibiotic regimens, cut costs, and preserve future ...

Even superbugs have their kryptonite. Two types of lab-made molecules make drug-resistant bacteria susceptible to antibiotics again, researchers report March 9 in Science Translational Medicine. The ...

Focusing on the human pathogen Staphylococcus aureus, new research led by scientists from the University of Sheffield in the U.K., examines how bacteria maintain their unique cell walls and how ...

First-line antibiotics for uncomplicated urinary tract infection (UTI) remain more effective than fluoroquinolones and beta-lactams, with a 1.78% lower risk for 30-day revisits than fluoroquinolones ...

It’s a story 30-odd years in the making. The tale begins in the 1990s, when Roche had an anti-infectives unit. Back then, plenty of pharmaceutical companies had scientists working on novel antibiotics ...